Bill Bradford, MD, PhD

Dr. Bill Bradford is a biopharmaceutical industry advisor with more than 25 years of experience in executive leadership, product development, medical affairs, and board director roles. Bill is Principal at Teton Bioscience and has provided drug development and strategic advisory services since 2015. He co-founded Indalo Therapeutics, a clinical-stage fibrosis company, served as a Board Director, and was Chief Medical Officer until 2020. Bill also served as Senior Vice President, Clinical Development at InterMune, Inc. (acquired by Roche) where he led the successful development of Esbriet® for Idiopathic Pulmonary Fibrosis and advanced a product development portfolio spanning a range of therapeutic areas. Earlier in his career, Bill held product development positions at Genentech (member of the Roche Group) and IntraBiotics Pharmaceuticals, and was an infectious disease specialist and researcher at the University of California San Francisco (UCSF). Dr. Bradford serves on the Board of Directors of Endeavor BioMedicines and the Bluefield Project, recently served on the Boards of Virion Therapeutics and Hennepin Life Sciences, and is a member of multiple scientific advisory boards. Bill graduated cum laude from Williams College, received his M.D. from the University of North Carolina School of Medicine and has a doctorate in epidemiology from University of California, Berkeley. Bill completed his internal medicine residency and infectious disease fellowship at UCSF.